COMMUNIQUÉS West-GlobeNewswire
-
Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
28/04/2026 -
BioCardia Announces Allowance of Japanese Patent on Proprietary Heart3D™ Fusion Imaging Software for Procedure Planning and Realtime Navigation During CardiAMP Cell Therapy Procedures
28/04/2026 -
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
28/04/2026 -
Theolytics Announces First Patient Dosed in the OCTOPOD-IP Trial, a US Phase 1 Trial with THEO-260, a Novel Oncolytic Immunotherapy Targeting Ovarian Cancer
28/04/2026 -
Dr. Björn Zoëga: Scaling Integrated Digital Systems Will Define the Future of Healthcare
28/04/2026 -
KFSH Awards Innovation Challenge Winners at C3 Davos of Healthcare™ Silicon Valley Summit
28/04/2026 -
Reacta Healthcare Announces Expansion into Asia-Pacific and Appoints Professor Gary Wing-Kin Wong to Advisory Board
28/04/2026 -
Transactions in connection with share buy-back program
28/04/2026 -
Holivita Launches a New Platform, Offering a Human-Centric Blueprint for Health Through AI and Your DNA
28/04/2026 -
Clariane annonce l’offre de 230 millions d’euros d’obligations senior additionnelles en vue de refinancer ses obligations hybrides vertes perpetuelles
28/04/2026 -
Yinuo Chen, founder of three major Fertility centers—Tulip, ONELIFE, and Sino—was invited to participate in the Shanghai Medical Exhibition
28/04/2026 -
Clariane has launched a proposed offering of €230 million of additional senior notes to refinance its hybrid green perpetual bonds
28/04/2026 -
Dr. Petros Kotsidis: KFSH Positions AI as a Scalable Model for Real-World Healthcare Innovation
28/04/2026 -
Santhera Announces Positive AIFA Board Decision on Reimbursement of AGAMREE® (vamorolone) in Italy
28/04/2026 -
Idorsia reports strong Q1 2026 performance with 74% QUVIVIQ sales growth year-on-year
28/04/2026 -
Santhera Pharmaceuticals Full Year Results for the Year Ended 31 December 2025
28/04/2026 -
Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial
28/04/2026 -
CORE Soft Tissue Therapy Reports Full Booking Capacity in First Year as Referral Growth Supports South London Expansion
28/04/2026 -
Scancell receives FDA Fast Track Designation for iSCIB1+ in advanced melanoma and provides data update from its SCOPE Phase 2 study
28/04/2026
Pages